XCath
"Next-Gen Endovascular Robotics"
Endovascular robotics and steerable neurovascular guidewires for minimally invasive vascular treatment
XCath develops next-generation endovascular robotic systems and steerable guidewires targeting life-threatening cerebrovascular conditions including brain aneurysms and stroke. Founded in 2017 as a spinout from UTHealth's Microsurgical Robotics Laboratory, the company is headquartered in Houston, Texas, with an additional campus in Pangyo, South Korea. Its Iris endovascular robotic system achieved the world's first intracranial robotic navigation and successfully completed first-in-human brain aneurysm procedures in 2025.
XCath has raised over ninety-two million dollars in total funding including a thirty-million-dollar Series C round, and is advancing its platform toward broader clinical deployment in neurointerventional care.
Primary type & automation activities this supplier delivers:
Iris Endovascular Robotic System
Endovascular robotic system for minimally invasive neurovascular treatment including brain aneurysms
Contact XCath
WEBSITE
https://xcath.comHEADQUARTERS
United States
Company Facts
Founded
2017
Primary Role
Manufacturer
Company Size
-
Primary Region
North America
Annual Sales
-
Funding Stage
-
Funding Total
-
